https://www.prognyx.com/blog/per-endpoints-merck-s-welireg-lenvima-wins-fda-approval-in-advanced-ccrccPrognyxen2026-09-25Per Endpoints, Merck's Welireg-Lenvima wins FDA approval in advanced ccRCC https://www.prognyx.com/blog/per-endpoints-elevar-s-lyrfigtu-wins-first-fda-nod-in-fgfr2-bile-duct-cancerPrognyxen2026-09-24Per Endpoints, Elevar's Lyrfigtu wins first FDA nod in FGFR2 bile duct cancer